Oct
24
2022
J&J, Alkermes, AbbVie, others set to benefit from expanding schizophrenia drug market
An increase in the patient population combined with new therapies in development means that schizophrenia drug market will soar to $13B in 2031 from $9B in 2021, according to GlobalData.